보고서 요약(국문)

개요
전 세계 희귀 신경 질환 치료제 시장은 2023년 1,394억 달러에 달했으며, 2024년부터 2031년까지 연평균 8.6%의 성장률을 보이며 2031년에는 2,697억 달러에 이를 것으로 예상됩니다.
희귀 신경 질환은 희귀 신경 장애 또는 고아 신경 장애라고도 하며, 신경계에 영향을 미치는 다양하고 특이한 질환들을 포괄합니다. 희귀 신경 질환은 주로 중추 및 말초 신경계와 근육에 영향을 미치는 이질적인 질환군입니다. 이러한 질환은 유병률이 낮아 "희귀" 질환으로 분류되며, 일반적으로 2,000명 중 1명 미만에게 발생하는 질환으로 정의됩니다.
인체의 신경계를 표적으로 하는 희귀 신경 질환에는 뇌와 척수가 포함됩니다. 아이카르디 증후군, 아이카르디-구티에르 증후군, 반사성 교감신경 이영양증 증후군, 바탈리아-네리 증후군, 크로이츠펠트-야콥병, 실인증 등 다양한 희귀 신경 질환이 있습니다.
희귀 신경 질환 치료에는 인지 행동 치료, 대인 관계 심리 치료, 사이버나이프 등 다양한 치료법이 사용됩니다. 레베티라세탐(케프라), 토피라메이트(토파맥스), 라모트리진(라믹탈), 옥스카르바제핀(트리렙탈), 디발프로엑스 나트륨(데파코트)과 같은 약물도 사용됩니다.
시장 동향: 주요 동인
희귀 신경 질환 유병률 증가
전 세계 희귀 신경 질환 치료제 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 그중 가장 중요한 요인은 희귀 신경 질환의 유병률 증가입니다. 세계보건기구(WHO)에 따르면 2024년 5월 기준으로 3명 중 1명 이상이 신경계 질환의 영향을 받았으며, 이는 전 세계적으로 질병과 장애의 주요 원인입니다.
일부 희귀 신경계 질환에는 근위축성 측삭 경화증(ALS), 뒤센 근디스트로피, 수직주시마비, 헌팅턴병 등이 있습니다. 2023년 11월에 발표된 Orphanet 보고서에 따르면, 유럽에서 만성 염증성 탈수초성 다발신경병증의 유병률은 인구 10만 명당 3.7명이며, 루게릭병(ALS)의 유병률은 전 세계적으로 3.85명, 유럽연합(EU)에서는 5.2명입니다. 같은 자료에 따르면, 헌팅턴병의 유병률은 2023년 EU에서 12.0명입니다.
또한, 파트너십 및 협력, 임상 시험 증가, 연구 조사, 제품 출시 및 승인과 같은 주요 기업들의 전략이 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2023년 7월 Biogen Inc.와 Reata Pharmaceuticals, Inc.는 Biogen이 Reata를 주당 172.50달러(현금)에 인수하는 최종 계약을 체결했다고 발표했는데, 이는 약 73억 달러의 기업 가치를 반영합니다.

또한, 국제적인 희귀의약품 개발 및 상용화 회사인 오르팔란(Orphalan SA)은 2023년 4월 미국에서 쿠브리오르(Cuvrior)의 상용화를 발표했습니다. 쿠브리오르는 새로운 트리엔틴 테트라하이드로클로라이드(TETA-4HCl) 제제로, 구리 제거 후 D-페니실아민에 내성이 생긴 안정적인 윌슨병 성인 환자 치료에 사용 가능합니다.
마찬가지로, 2023년 4월 바이오젠(Biogen Inc)은 미국 식품의약국(FDA)이 슈퍼옥사이드 디스뮤타제 1(SOD1) 유전자 변이가 있는 성인 근위축성 측삭경화증(ALS) 환자 치료를 위한 퀄소디(QALSODY, 토퍼센) 100mg/15mL 주사제를 승인했다고 발표했습니다.
제한 요인
높은 치료 비용, 엄격한 규제 요건, 인식 및 진단 부족, 적은 환자 수, 제한된 치료 옵션, 보험 적용 문제, 숙련되고 훈련된 의료 전문가 부족 등의 요인이 시장 성장을 저해할 것으로 예상됩니다.
본 보고서에 대한 자세한 내용은 샘플을 요청해 주십시오.
세그먼트 분석
전 세계 희귀 신경 질환 치료제 시장은 약물 유형, 투여 경로, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
소분자 약물 부문은 전 세계 희귀 신경 질환 치료제 시장 점유율의 약 64.3%를 차지했습니다.
소분자 약물 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 소분자 약물은 희귀 신경 질환 치료에 적합한 여러 가지 장점을 가지고 있습니다. 크기가 작아 혈뇌 장벽을 쉽게 통과하고 중추 신경계 내 세포 표적에 접근할 수 있습니다.
이를 통해 희귀 신경 질환과 관련된 특정 단백질 기능을 조절할 수 있습니다. 또한, 소분자 약물은 대형 생물학적 약물에 비해 더 빠르고 비용 효율적으로 제조할 수 있습니다.
더불어, 업계 주요 기업들의 파트너십 및 협력, 제품 승인, 재정 투자와 같은 전략이 이 시장 성장을 견인할 것입니다. 예를 들어, 2024년 4월 입센(Ipsen)과 스카이호크 테라퓨틱스(Skyhawk Therapeutics)는 희귀 신경 질환 치료를 위해 RNA를 조절하는 새로운 소분자 화합물을 발굴 및 개발하기 위한 전 세계 독점 협력 계약을 체결했다고 발표했습니다.
마찬가지로, 2024년 1월 바이오젠(Biogen Inc.)은 단기 및 장기적인 성장을 견인할 것으로 예상되는 전략적 치료 분야인 알츠하이머병(AD)에 자원을 재집중할 계획을 발표했습니다. 바이오젠은 미국 식품의약국(FDA)의 전통적인 승인을 받은 최초의 항아밀로이드 베타 치료제인 레첵비(LEQEMBI, lecanemab-irmb)의 개발을 지속하고, 타우를 표적으로 하는 ASO(BIIB080)와 타우 응집을 억제하는 경구용 소분자 억제제(BIIB113)를 포함한 잠재적인 새로운 치료법 개발을 가속화할 예정입니다.
또한, 2023년 3월 라포트 테라퓨틱스(Rapport Therapeutics)는 신경 질환 치료를 위한 정밀 표적 소분자 약물 발굴 플랫폼을 지원하기 위해 1억 달러 규모의 시리즈 A 투자를 유치하며 출범했습니다.

지리적 분석
북미는 전 세계 희귀 신경 질환 치료제 시장의 약 44.3%를 차지했습니다.
북미 지역은 희귀 신경 질환 발병률 증가, 희귀 질환 치료에 대한 보험 적용, 그리고 연구 개발(R&D) 투자 확대 등으로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다.
미국 식품의약국(fda.gov)에 따르면, 2023년 2월 기준 희귀 질환은 미국 내 환자 수가 20만 명 미만인 질환을 의미합니다. 약 2,500만~3,000만 명의 미국인(약 10명 중 1명)이 희귀 질환을 앓고 있으며, 많은 희귀 질환은 치료 옵션이 거의 없거나 전혀 없습니다.
또한, 주요 기업들의 시장 진출, 잘 발달된 의료 인프라, 그리고 정부의 인식 개선 프로그램과 같은 정책들이 이 시장 성장을 견인할 것입니다. 예를 들어, 2024년 6월 뉴로진(Neurogene Inc.)은 레트 증후군(Rett syndrome) 치료제인 NGN-401 유전자 치료제가 미국 식품의약국(FDA)의 희귀질환 치료제 임상시험 지원(START) 시범 프로그램에 선정되었다고 발표했습니다.
마찬가지로, 2022년 5월 CDER은 희귀질환 치료 가속화(ARC) 프로그램을 시작했습니다. ARC 프로그램은 CDER의 집단적인 전문 지식과 활동을 활용하여 희귀질환에 대한 과학적 및 규제적 혁신을 추진하는 것을 목표로 합니다.
또한, 임상시험, 제품 출시 및 승인 건수의 증가는 이 지역 시장 성장을 촉진할 것입니다. 예를 들어, 2023년 3월 FDA는 리아타(Reata)의 스카이클라리스(Skyclarys, 오모벨록솔론)를 프리드라이히 운동실조증(Friedreich’s ataxia, FA) 치료제로 승인했습니다. FA는 청소년기에 발병하여 환자를 휠체어에 의존하게 만들고 종종 수명을 단축시키는 유전성 신경 질환입니다. 스카이클라리스는 레트 증후군 치료를 위해 승인된 최초의 약물이 되었으며, 이 질환은 미국에서 약 5,000명, 전 세계적으로 약 22,000명에게 진단되었습니다.
또한, 2022년 9월 아카디아 파마슈티컬스는 트로피네티드의 레트 증후군 치료제 신약 신청서가 미국 식품의약국(FDA)에 접수 및 심사 대상으로 승인되었다고 발표했습니다.
마찬가지로, 2024년 6월 루시 테라퓨틱스는 잠재적으로 새로운 약물을 개발하고 신경 질환 연구 프로그램을 발전시키기 위해 1,250만 달러의 추가 자금을 조달했다고 발표했습니다.

시장 세분화
약물 유형별
• 생물학적 제제
• 저분자 의약품
투여 경로별
• 정맥 주사
• 경구 투여
적용 분야별
• 드라벳 증후군
• 부신백질이영양증
• 기면증
• 앤젤만 증후군
• 근위축성 측삭 경화증
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
희귀 신경 질환 치료제 시장의 주요 글로벌 업체로는 Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc. 등이 있습니다. 미국 기업으로는 WorldMeds LLC(Solstice Neurosciences LLC), Aquestive Therapeutics Inc., Sanofi S.A., Merck & Co., Inc., CSL Ltd, Merz Pharma GmbH & Co. KGaA, Kedrion Biopharma Inc. 등이 있습니다.
주요 개발 사항
 2024년 5월, Biogen Inc.는 유럽 위원회(EC)가 SOD1 유전자 변이(SOD1-ALS)와 관련된 근위축성 측삭 경화증(ALS) 성인 환자 치료를 위한 QALSODY(토퍼센)에 대해 예외적인 상황에서의 판매 허가를 승인하고 희귀 질환 지정을 유지했다고 발표했습니다.

 2024년 4월, NS Pharma는 MiNA Therapeutics와 중추신경계 희귀 질환 치료제 개발을 위한 연구 제휴를 발표했습니다.

 2024년 2월, 로슈 파마 인디아는 다발성 경화증(MS) 치료를 위한 블록버스터급 신약인 오크레부스(오크렐리주맙) 출시를 발표하며, 인도에서 이 질병으로 고통받는 수많은 환자들의 미충족 수요를 충족하기 위해 신경과 포트폴리오를 확장했습니다.
 2023년 9월, 하모니 바이오사이언스 홀딩스는 미국 식품의약국(FDA)이 특발성 과다수면증(IH) 치료를 위한 피톨리산트를 희귀의약품으로 지정했다고 발표했습니다.

보고서 구매 이유:

• 약물 유형, 투여 경로, 적용 분야, 유통 채널 및 지역별 글로벌 희귀 신경 질환 치료제 시장 세분화를 시각화하고 주요 상업적 자산 및 기업을 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 글로벌 희귀 신경 질환 치료제 시장의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 Excel 파일로 제공됩니다.
글로벌 희귀 신경 질환 치료제 시장 보고서는 약 69개의 표, 68개의 그림, 그리고 183페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global rare neurological disease drugs market reached US$ 139.4 billion in 2023 and is expected to reach US$ 269.7 billion by 2031 growing with a CAGR of 8.6% during the forecast period 2024-2031.
Rare neurological diseases, also referred to as rare neurologic disorders or orphan neurological disorders, are a range of unusual and varied conditions that impact the nervous system. Rare neurological diseases are a heterogeneous group of disorders that primarily affect the central and peripheral nervous systems, as well as the muscles. These conditions are considered "rare" due to their low prevalence, typically defined as affecting less than 1 in 2,000 people.
Rare neurological diseases that target the nervous system of the human body include the brain and spinal cord. There are various rare neurological disorders such as Aicardi syndrome, Aicardi-Goutieres syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri syndrome, Creutzfeldt Jakob Disease, Agnosia, and many others.
There are various therapies used for the treatment of rare neurological diseases drugs such as cognitive behavioral therapy, interpersonal psychotherapy, cyberknife, and others. Drugs such as levetiracetam (Keppra), topiramate (Topamax), lamotrigine (Lamictal), oxcarbazepine (Trileptal), and divalproex sodium (Depakote).
Market Dynamics: Drivers
Increasing Prevalence of Rare Neurological Diseases
The demand for the global rare neurological disease drugs market is driven by multiple factors. One of the primary factors is the increasing prevalence of rare neurological diseases. According to the World Health Organization (WHO), in May 2024, over 1 in 3 people were affected by neurological conditions, the leading cause of illness and disability worldwide.
Some rare neurological diseases include amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, Vertical gaze palsy, and Huntington's disease, among others. As per the Orphanet report published in November 2023, the prevalence of chronic inflammatory demyelinating polyneuropathy is 3.7 per 100,000 individuals in Europe, and the prevalence of ALS is 3.85 worldwide and 5.2 in the European Union (EU) in 2023. As per the same source, the prevalence of Huntington's disease is 12.0 in the EU in 2023.
Furthermore, key players' strategies such as partnerships & collaborations, a rising number of clinical trials, research studies, and product launches & approvals are expected to propel the market growth. For instance, in July 2023, Biogen Inc. Reata Pharmaceuticals, Inc. announced the companies had entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
Also, in April 2023, Orphalan SA, an international orphan drug development and commercialization company, announced the commercial launch in the U.S. for Cuvrior. It is a new trientine tetrahydrochloride (TETA-4HCl). It is now available for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to D-penicillamine.
Similarly, in April 2023, Biogen Inc announced that the U.S. Food and Drug Administration (FDA) has approved QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.
Restraints
Factors such as the high cost of treatment, stringent regulatory requirements, lack of awareness & diagnosis, small patient population, limited treatment options, reimbursement challenges, and lack of skilled & trained healthcare professionals are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global rare neurological disease drugs are segmented based on drug type, route of administration, application, distribution channel, and region.
The small molecules segment accounted for approximately 64.3% of the global rare neurological disease drugs market share
The small molecules segment is expected to hold the largest market share over the forecast period. Small molecule drugs have several advantages that make them well-suited for rare neurological disease treatments. Their small size allows them to easily penetrate the blood-brain barrier and access intracellular targets within the central nervous system.
This enables the modulation of specific protein functions implicated in rare neurological disorders. Additionally, small molecules can be manufactured more quickly and cost-effectively compared to larger biological drugs.
Moreover, key players in the industry strategies such as partnerships & collaborations, product approvals, and financial investments would drive this market growth. For instance, in April 2024, Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Similarly, in January 2024, Biogen Inc. announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will continue to advance LEQEMBI (lecanemab-irmb), the first anti-amyloid beta treatment with FDA traditional approval in the United States, and will accelerate the development of potential new treatment modalities, including its ASO targeting tau (BIIB080) and an oral small molecule inhibitor of tau aggregation (BIIB113).
Also, in March 2023, Rapport Therapeutics launched with $100 million in a series A financing to support its novel platform to discover precision-targeted small molecule drugs to treat neurological disorders.
Geographical Analysis
North America accounted for approximately 44.3% of the global rare neurological disease drugs market share
North American region is expected to hold the largest market share over the forecast period owing to the growing incidence of rare neurological disorders, availability of reimbursement for the treatment of rare diseases, and increasing research and development (R&D) in the region.
As fda.gov stated in February 2023, a rare disease is any disease that affects fewer than 200,000 people in the U.S. Approximately 25 to 30 million Americans are living with a rare disease (about 1 in 10 people), and many rare diseases have few or no available treatment options.
Moreover, a major number of key players' presence, well-advanced healthcare infrastructure, and government initiatives such as awareness programs would drive this market growth. For instance, in June 2024, Neurogene Inc. announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program.
Similarly, in May 2022, CDER launched the Accelerating Rare Disease Cures (ARC) Program. The ARC Program seeks to harness CDER’s collective expertise and activities to drive scientific and regulatory innovation for rare diseases.
In addition, the rising number of clinical trials, product launched and approvals would propel this market growth in this region. For instance, in March 2023, The FDA signed off on Reata’s Skyclarys (omoveloxolone) for the treatment of Friedreich’s ataxia (FA), a hereditary neurological disorder that strikes during adolescence and leaves patients wheelchair-bound and often cuts short their lives. Skyclarys became the first drug approved for the condition, which affects roughly 5,000 who have been diagnosed in the United States and 22,000 worldwide.
Also, in September 2022, Acadia Pharmaceuticals announced Trofinetide's new drug application for the treatment of Rett syndrome has been accepted for filing and review by the U.S. FDA
Similarly, in June 2024, Lucy Therapeutics announced it has raised $12.5m in additional funding to develop potentially new drugs and advance the company’s research programs for neurological diseases.
Market Segmentation
By Drug Type
• Biologics
• Small Molecules
By Route of Administration
• Intravenous
• Oral
By Application
• Dravet syndrome
• Adrenoleukodystrophy
• Narcolepsy
• Angelman syndrome
• Amyotrophic Lateral Sclerosis
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the rare neurological disease drugs market include Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Aquestive Therapeutics Inc., Sanofi S.A., Merck & Co., Inc., CSL Ltd, Merz Pharma GmbH & Co. KGaA, and Kedrion Biopharma Inc. among others.
Key Developments
 In May 2024, Biogen Inc announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS).
 In April 2024, NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System.
 In February 2024, Roche Pharma India announced the launch of its blockbuster breakthrough drug, Ocrevus (Ocrelizumab), for the treatment of multiple sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of numerous patients grappling with this debilitating disease in India
 In September 2023, Harmony Biosciences Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisantf for the treatment of idiopathic hypersomnia (IH).
Why Purchase the Report?
• To visualize the global rare neurological disease drugs market segmentation based on drug type, route of administration, application, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global rare neurological disease treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global rare neurological disease drugs market report would provide approximately 69 tables, 68 figures, and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Rare Neurological Diseases
4.1.1.2. Innovative Development of New Drugs for Rare Neurological Diseases
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Biologics
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Small Molecules
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Intravenous*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Dravet syndrome *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adrenoleukodystrophy
8.4. Narcolepsy
8.5. Angelman syndrome
8.6. Amyotrophic Lateral Sclerosis
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer, Inc
12.3. Johnson & Johnson Services, Inc
12.4. US WorldMeds LLC (Solstice Neurosciences LLC)
12.5. Aquestive Therapeutics Inc
12.6. Sanofi S.A.
12.7. Merck & Co., Inc
12.8. CSL Ltd
12.9. Merz Pharma GmbH & Co. KGaA
12.10. Kedrion Biopharma Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Novartis AG, 4.	Key Developments, Pfizer, Inc, Johnson & Johnson Services, Inc, US WorldMeds LLC (Solstice Neurosciences LLC), Aquestive Therapeutics Inc, Sanofi S.A., Merck & Co., Inc, CSL Ltd, Merz Pharma GmbH & Co. KGaA, Kedrion Biopharma Inc

표 목록 (Tables)

List of Tables

Table 1 Global Rare Neurological Disease Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Rare Neurological Disease Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Rare Neurological Disease Drugs Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Rare Neurological Disease Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Rare Neurological Disease Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 8 Global Rare Neurological Disease Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 10 Global Rare Neurological Disease Drugs Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 12 Global Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 14 Global Rare Neurological Disease Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Rare Neurological Disease Drugs Market Value, By Region, 2022-2031(US$ Million)

Table 16 North America Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 17 North America Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 18 North America Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 19 North America Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 20 North America Rare Neurological Disease Drugs Market Value, By Country, 2022-2031(US$ Million)

Table 21 South America Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 22 South America Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 23 South America Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 24 South America Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 25 South America Rare Neurological Disease Drugs Market Value, By Country, 2022-2031(US$ Million)

Table 26 Europe Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 27 Europe Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 28 Europe Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 29 Europe Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 30 Europe Rare Neurological Disease Drugs Market Value, By Country, 2022-2031(US$ Million)

Table 31 Asia-Pacific Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 32 Asia-Pacific Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 33 Asia-Pacific Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 34 Asia-Pacific Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 35 Asia-Pacific Rare Neurological Disease Drugs Market Value, By Country, 2022-2031(US$ Million)

Table 36 Middle East & Africa Rare Neurological Disease Drugs Market Value, By Drug Type, 2022-2031(US$ Million)

Table 37 Middle East & Africa Rare Neurological Disease Drugs Market Value, By Route of Administration, 2022-2031(US$ Million)

Table 38 Middle East & Africa Rare Neurological Disease Drugs Market Value, By Application, 2022-2031(US$ Million)

Table 39 Middle East & Africa Rare Neurological Disease Drugs Market Value, By Distribution Channel, 2022-2031(US$ Million)

Table 40 Novartis AG: Overview

Table 41 Novartis AG: Product Portfolio

Table 42 Novartis AG: Key Developments

Table 43 Pfizer, Inc.: Overview

Table 44 Pfizer, Inc.: Product Portfolio

Table 45 Pfizer, Inc.: Key Developments

Table 46 Johnson & Johnson Services, Inc.: Overview

Table 47 Johnson & Johnson Services, Inc.: Product Portfolio

Table 48 Johnson & Johnson Services, Inc.: Key Developments

Table 49 US WorldMeds LLC (Solstice Neurosciences LLC): Overview

Table 50 US WorldMeds LLC (Solstice Neurosciences LLC): Product Portfolio

Table 51 US WorldMeds LLC (Solstice Neurosciences LLC): Key Developments

Table 52 Aquestive Therapeutics Inc.: Overview

Table 53 Aquestive Therapeutics Inc.: Product Portfolio

Table 54 Aquestive Therapeutics Inc.: Key Developments

Table 55 Sanofi S.A.: Overview

Table 56 Sanofi S.A.: Product Portfolio

Table 57 Sanofi S.A.: Key Developments

Table 58 Merck & Co., Inc.: Overview

Table 59 Merck & Co., Inc.: Product Portfolio

Table 60 Merck & Co., Inc.: Key Developments

Table 61 CSL Ltd: Overview

Table 62 CSL Ltd: Product Portfolio

Table 63 CSL Ltd: Key Developments

Table 64 Merz Pharma GmbH & Co. KGaA: Overview

Table 65 Merz Pharma GmbH & Co. KGaA: Product Portfolio

Table 66 Merz Pharma GmbH & Co. KGaA: Key Developments

Table 67 Kedrion Biopharma Inc.: Overview

Table 68 Kedrion Biopharma Inc.: Product Portfolio

Table 69 Kedrion Biopharma Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 2 Global Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 3 Global Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 4 Global Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 5 Global Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 6 Global Rare Neurological Disease Drugs Market Share, By Region, 2023 & 2031(%)

Figure 7 Global Rare Neurological Disease Drugs Market Y-o-Y Growth, By Drug Type, 2023-2031 (%)

Figure 8 Biologics Rare Neurological Disease Treatment Market Value, 2022-2031(US$ Million)

Figure 9 Small Molecules Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 10 Global Rare Neurological Disease Drugs Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 11 Intravenous Route of Administration in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 12 Oral Route of Administration in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 13 Global Rare Neurological Disease Drugs Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 14 Dravet Syndrome Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 15 Adrenoleukodystrophy Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 16 Narcolepsy Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 17 Angelman syndrome Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 18 Amyotrophic Lateral Sclerosis Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 19 Others Application in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 20 Global Rare Neurological Disease Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 23 Online Pharmacies Distribution Channel in Global Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 24 Global Rare Neurological Disease Drugs Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 25 North America Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 26 Asia-Pacific Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 27 Europe Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 28 South America Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 29 Middle East and Africa Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 30 North America Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 31 North America Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 32 North America Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 33 North America Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 34 North America Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 35 North America Rare Neurological Disease Drugs Market Share, By Country, 2023 & 2031(%)

Figure 36 South America Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 37 South America Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 38 South America Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 39 South America Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 40 South America Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 41 South America Rare Neurological Disease Drugs Market Share, By Country, 2023 & 2031(%)

Figure 42 Europe Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 43 Europe Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 44 Europe Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 45 Europe Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 46 Europe Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 47 Europe Rare Neurological Disease Drugs Market Share, By Country, 2023 & 2031(%)

Figure 48 Asia-Pacific Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 49 Asia-Pacific Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 50 Asia-Pacific Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 51 Asia-Pacific Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 52 Asia-Pacific Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 53 Asia-Pacific Rare Neurological Disease Drugs Market Share, By Country, 2023 & 2031(%)

Figure 54 Middle East & Africa Rare Neurological Disease Drugs Market Value, 2022-2031(US$ Million)

Figure 55 Middle East & Africa Rare Neurological Disease Drugs Market Share, By Drug Type, 2023 & 2031(%)

Figure 56 Middle East & Africa Rare Neurological Disease Drugs Market Share, By Route of Administration, 2023 & 2031(%)

Figure 57 Middle East & Africa Rare Neurological Disease Drugs Market Share, By Application, 2023 & 2031(%)

Figure 58 Middle East & Africa Rare Neurological Disease Drugs Market Share, By Distribution Channel, 2023 & 2031(%)

Figure 59 Novartis AG: Financials

Figure 60 Pfizer, Inc.: Financials

Figure 61 Johnson & Johnson Services, Inc.: Financials

Figure 62 US WorldMeds LLC (Solstice Neurosciences LLC): Financials

Figure 63 Aquestive Therapeutics Inc.: Financials

Figure 64 Sanofi S.A.: Financials

Figure 65 Merck & Co., Inc.: Financials

Figure 66 CSL Ltd: Financials

Figure 67 Merz Pharma GmbH & Co. KGaA: Financials

Figure 68 Kedrion Biopharma Inc.: Financials

세계 희귀 신경 질환 치료 시장 – 2024-2031년

Global Rare Neurological Disease Treatment Market - 2024-2031